AltimmuneALT
ALT
About: Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Employees: 59
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
68% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 22
51% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 43
43% more call options, than puts
Call options by funds: $23M | Put options by funds: $16.1M
20% more capital invested
Capital invested by funds: $243M [Q3] → $292M (+$49M) [Q4]
7% more funds holding
Funds holding: 168 [Q3] → 180 (+12) [Q4]
1.3% more ownership
Funds ownership: 55.57% [Q3] → 56.87% (+1.3%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
132%
upside
Avg. target
$18.50
258%
upside
High target
$25
384%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 21% 1-year accuracy 40 / 187 met price target | 132%upside $12 | Buy Reiterated | 3 Apr 2025 |
Citizens Capital Markets Jonathan Wolleben 47% 1-year accuracy 32 / 68 met price target | 384%upside $25 | Market Outperform Reiterated | 2 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
6 hours ago
Altimmune to Participate in the Citizens Life Sciences Conference
GAITHERSBURG, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Citizens Life Sciences Conference. Details are as follows:
Positive
The Motley Fool
1 month ago
Buying These Dirt-Cheap Stocks Could Be a Brilliant Move
Valuation always matters in investing. And sometimes you can find stocks that are especially great bargains.
Positive
Seeking Alpha
1 month ago
Altimmune: Pemvidutide Differentiation Advancement In MASH Space Continues To Shine
Altimmune, Inc.'s top-line data from the phase 2b IMPACT study using pemvidutide for the treatment of patients with MASH expected in Q2 of 2025. The global non-alcoholic steatohepatitis [NASH] market could reach $39.3 billion by 2031. Company received IND clearance from the FDA to advance two mid-stage studies using pemvidutide to target patients with AUD and ALD; First phase 2 study to start in mid-2025.
Positive
Reuters
1 month ago
Altimmune to test obesity drug for alcohol use disorder and related health conditions
Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver disease.
Neutral
GlobeNewsWire
1 month ago
Altimmune to Host Virtual R&D Day on March 13, 2025
Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA Program to Feature Presentations from Renowned KOLs in Obesity, MASH and Two Additional Indications for Pemvidutide following recent IND Clearances by FDA
Neutral
GlobeNewsWire
1 month ago
Altimmune to Participate in the Leerink Global Healthcare Conference
GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company's management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows:
Positive
Seeking Alpha
2 months ago
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due Q2
Altimmune's pemvidutide shows promise in treating MASH with obesity, potentially positioning it as a first-in-class drug targeting both liver health and weight loss. Despite past volatility, ALT stock has stabilized, with recent data showing significant weight loss at higher doses, sparking renewed investor interest. Altimmune's Q4 2024 earnings reveal a net loss of $23.2m, with $131.9m in cash, highlighting the company's ongoing financial challenges and reliance on future clinical success.
Neutral
Seeking Alpha
2 months ago
Altimmune, Inc. (ALT) Q4 2024 Earnings Call Transcript
Altimmune, Inc. (NASDAQ:ALT ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Lee Roth - President, Burns McClellan, Investor Relations Advisors Vipin Garg - Chief Executive Officer Scott Harris - Chief Medical Officer Greg Weaver - Chief Financial Officer Scot Roberts - Chief Scientific Officer Conference Call Participants Yasmeen Rahimi - Piper Sandler Annabel Samimy - Stifel Liisa Bayko - Evercore William Wood - B. Riley Securities Jonathan Wolleben - Citizens JMP Patrick Trucchio - H.C.
Neutral
GlobeNewsWire
2 months ago
Altimmune Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Top-line data from Phase 2b IMPACT trial of pemvidutide in metabolic dysfunction-associated steatohepatitis (MASH) to be reported in Q2 2025 Investigational New Drug (IND) applications in two additional indications have received FDA clearance, with Phase 2 trials to commence mid-2025 Company to hold virtual R&D Day on March 13, 2025. Program will include KOL presentations on pemvidutide development in obesity, MASH and additional indications Two pharmaceutical industry veterans added to Company Board of Directors Cash, cash equivalents and short-term investments of $131.9 million on December 31, 2024 Webcast to be held today, February 27, 2025, at 8:30 a.m.
Neutral
GlobeNewsWire
2 months ago
Seasoned Biopharmaceutical Industry Executives Teri Lawver and Jerry Durso Appointed to Altimmune Board of Directors
Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar Immunology and Cardiovascular & Metabolism Portfolios over her 20-year career
Charts implemented using Lightweight Charts™